stockportfolio.pro logostockportfolio.pro
Stocks Screener Start 7-day free trial
Stocks / ADMA / Revenue

ADMA Biologics, Inc. Revenue 2011–2025

ADMA Biologics, Inc. (ADMA) annual revenue by fiscal year, computed from SEC filings. Compound growth +59.2%/yr over 14 years.

Fiscal yearRevenueChange (YoY)
FY 2025$510.17M+19.6%
FY 2024$426.45M+65.2%
FY 2023$258.21M+67.6%
FY 2022$154.08M+90.4%
FY 2021$80.94M+91.7%
FY 2020$42.22M+43.9%
FY 2019$29.35M+72.8%
FY 2018$16.99M-25.4%
FY 2017$22.76M+113.5%
FY 2016$10.66M+48.5%
FY 2015$7.18M+21.3%
FY 2014$5.92M+92.8%
FY 2013$3.07M+174.4%
FY 2012$1.12M+46.9%
FY 2011$761,042

Source: ADMA Biologics, Inc. SEC filings — income statement (10-K). Refreshed nightly.

See the full picture for ADMA Biologics, Inc.

Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.

Open the interactive view — free

ADMA Biologics, Inc. — frequently asked questions

What is ADMA Biologics, Inc.'s revenue?

ADMA Biologics, Inc. (ADMA) reported revenue of $510.17M for fiscal year 2025, per its SEC filings.

How has ADMA Biologics, Inc.'s revenue changed over time?

Between fiscal 2011 and 2025, ADMA's revenue grew at roughly 59.2% per year (compound annual rate), from $761,042 to $510.17M.

Where does this data come from?

Figures are computed from ADMA Biologics, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.

More ADMA financial history

Full ADMA fundamentals page → · All 1,500+ companies →